These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
234 related articles for article (PubMed ID: 32585229)
1. The therapeutic potential of targeting CD73 and CD73-derived adenosine in melanoma. Soleimani A; Farshchi HK; Mirzavi F; Zamani P; Ghaderi A; Amini Y; Khorrami S; Mashayekhi K; Jaafari MR Biochimie; 2020 Sep; 176():21-30. PubMed ID: 32585229 [TBL] [Abstract][Full Text] [Related]
2. Targeting Tumor-derived Exosomes Expressing CD73: New Opportunities in the Pathogenesis and Treatment of Cancer. Nooshabadi VT; Arab S Curr Mol Med; 2021; 21(6):476-483. PubMed ID: 33222670 [TBL] [Abstract][Full Text] [Related]
3. Targeting Metabolism of Extracellular Nucleotides via Inhibition of Ectonucleotidases CD73 and CD39. Jeffrey JL; Lawson KV; Powers JP J Med Chem; 2020 Nov; 63(22):13444-13465. PubMed ID: 32786396 [TBL] [Abstract][Full Text] [Related]
4. CD73: an emerging checkpoint for cancer immunotherapy. Chen S; Wainwright DA; Wu JD; Wan Y; Matei DE; Zhang Y; Zhang B Immunotherapy; 2019 Aug; 11(11):983-997. PubMed ID: 31223045 [TBL] [Abstract][Full Text] [Related]
5. Discovery of Potent and Selective Methylenephosphonic Acid CD73 Inhibitors. Sharif EU; Kalisiak J; Lawson KV; Miles DH; Newcomb E; Lindsey EA; Rosen BR; Debien LPP; Chen A; Zhao X; Young SW; Walker NP; Sträter N; Scaletti ER; Jin L; Xu G; Leleti MR; Powers JP J Med Chem; 2021 Jan; 64(1):845-860. PubMed ID: 33399453 [TBL] [Abstract][Full Text] [Related]
6. Targeting CD73 and downstream adenosine receptor signaling in triple-negative breast cancer. Allard B; Turcotte M; Stagg J Expert Opin Ther Targets; 2014 Aug; 18(8):863-81. PubMed ID: 24798880 [TBL] [Abstract][Full Text] [Related]
7. Measurement of CD73 enzymatic activity using luminescence-based and colorimetric assays. Allard B; Cousineau I; Spring K; Stagg J Methods Enzymol; 2019; 629():269-289. PubMed ID: 31727245 [TBL] [Abstract][Full Text] [Related]
8. Extracellular purine metabolism and signaling of CD73-derived adenosine in murine Treg and Teff cells. Romio M; Reinbeck B; Bongardt S; Hüls S; Burghoff S; Schrader J Am J Physiol Cell Physiol; 2011 Aug; 301(2):C530-9. PubMed ID: 21593451 [TBL] [Abstract][Full Text] [Related]
9. Dual Mechanisms of Novel CD73-Targeted Antibody and Antibody-Drug Conjugate in Inhibiting Lung Tumor Growth and Promoting Antitumor Immune-Effector Function. Jin R; Liu L; Xing Y; Meng T; Ma L; Pei J; Cong Y; Zhang X; Ren Z; Wang X; Shen J; Yu K Mol Cancer Ther; 2020 Nov; 19(11):2340-2352. PubMed ID: 32943546 [TBL] [Abstract][Full Text] [Related]
11. Intratumoral CD73: An immune checkpoint shaping an inhibitory tumor microenvironment and implicating poor prognosis in Chinese melanoma cohorts. Gao Z; Wang L; Song Z; Ren M; Yang Y; Li J; Shen K; Li Y; Ding Y; Yang Y; Zhou Y; Wei C; Gu J Front Immunol; 2022; 13():954039. PubMed ID: 36131912 [TBL] [Abstract][Full Text] [Related]
12. Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs. Allard B; Pommey S; Smyth MJ; Stagg J Clin Cancer Res; 2013 Oct; 19(20):5626-35. PubMed ID: 23983257 [TBL] [Abstract][Full Text] [Related]
13. Targeting the Immunomodulatory CD73/Adenosine System to Improve the Therapeutic Gain of Radiotherapy. de Leve S; Wirsdörfer F; Jendrossek V Front Immunol; 2019; 10():698. PubMed ID: 31024543 [TBL] [Abstract][Full Text] [Related]
15. The metabolic milieu in melanoma: Role of immune suppression by CD73/adenosine. Passarelli A; Tucci M; Mannavola F; Felici C; Silvestris F Tumour Biol; 2019 Apr; 42(4):1010428319837138. PubMed ID: 30957676 [TBL] [Abstract][Full Text] [Related]
16. Targeting CD73 limits tumor progression and enhances anti-tumor activity of anti-PD-1 therapy in intrahepatic cholangiocarcinoma. Sun BY; Zhang D; Gan W; Wu JF; Wang ZT; Sun GQ; Zhou J; Fan J; Yi Y; Hu B; Zhang BH; Qiu SJ J Cancer Res Clin Oncol; 2024 Jul; 150(7):348. PubMed ID: 39002018 [TBL] [Abstract][Full Text] [Related]
17. CD73 promotes proliferation and migration of human cervical cancer cells independent of its enzyme activity. Gao ZW; Wang HP; Lin F; Wang X; Long M; Zhang HZ; Dong K BMC Cancer; 2017 Feb; 17(1):135. PubMed ID: 28202050 [TBL] [Abstract][Full Text] [Related]
18. Enzyme activity of circulating CD73 in human serum. Morello S; Turiello R; Madonna G; Pinto A; Ascierto PA; Capone M Methods Enzymol; 2019; 629():257-267. PubMed ID: 31727244 [TBL] [Abstract][Full Text] [Related]
19. CD73 blockade enhances the local and abscopal effects of radiotherapy in a murine rectal cancer model. Tsukui H; Horie H; Koinuma K; Ohzawa H; Sakuma Y; Hosoya Y; Yamaguchi H; Yoshimura K; Lefor AK; Sata N; Kitayama J BMC Cancer; 2020 May; 20(1):411. PubMed ID: 32397971 [TBL] [Abstract][Full Text] [Related]
20. Design, synthesis and structure-activity relationship of malonic acid non-nucleoside derivatives as potent CD73 inhibitors. Shi C; Dai J; Chang L; Xu W; Huang C; Zhao Z; Li H; Zhu L; Xu Y Bioorg Med Chem Lett; 2024 Nov; 112():129946. PubMed ID: 39226996 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]